Phase I clinical trial - Mélanome uvéal et tumeurs oculaires
CLXS196X2101
Mélanome uvéal et tumeurs oculaires
Essai clinique fermé
Public cible
Adulte
A Phase I, Multi-center, Open-label, Study of LXS196, an Oral Protein Kinase C Inhibitor, in Patients With Metastatic Uveal Melanoma
Description de l'essai
This study is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumor activity of LXS196 as a single agent and in combination with HDM201 in patients with metastatic uveal melanoma.
Liens utiles
SOPHIE PIPERNO-NEUMANN
Investigateur principal